Operational Topic
Radiopharmaceutical treatments of canine skeletal conditions using 153Sm, 90Y, or
117m
Sn as the radionuclide do not require isolation of the treated animal from human
beings, but the 90Y and 117mSn treatments do require restrictions on prolonged, close
human interaction with the animals for 3 to 4 weeks after treatment.
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Abstract: The treatment of pets, service animals, and pre-clinical research subjects with
radionuclides raises concern for the safety of
the people who interact with the animals after
their treatment. Three treatments of skeletal
conditions in dogs are considered in this study:
153
Sm-1,4,7,10-tetraazacylcododecanetetramethylenephosphonic acid, which is a bone-seeking
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radiopharmaceutical; unencapsulated 90Y permanent interstitial implants, which are sometimes called “liquid brachytherapy”; and 117mSn
radiosynoviorthesis, which is also called radiosynovectomy. External exposure rate readings
of the 153Sm and 117mSn treatments, and Monte
Carlo simulations of 117mSn at a distance of 1
m and of all three in direct contact with tissue
were analyzed for doses. Dogs that have received
any of these treatments using typically administered activities may be released from radiation
safety isolation immediately after treatment
from the standpoint of external exposure. People
should avoid prolonged close proximity, such as
sleeping with a treated dog, for three weeks following an 90Y interstitial implant or for a month
following 117mSn radiosynoviorthesis. No such
avoidance is necessary after treatment with 153Sm1,4,7,10-tetraazacylcododecanetetramethylenephosphonic acid. Health Phys. 118(6):702–710;
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INTRODUCTION
The radiation safety of human beings is an important concern in the
administration of radioactive materials to veterinary patients and
preclinical research subjects. In
veterinary treatments that employ
relatively large amounts of radioactivity, a balance must be struck
between the radiation absorbed
dose to people after the animal is
released from radiation safety isolation and the well-being of the
animal, especially in the case of
pets and their families, if the animal is unaccustomed to being isolated from people. The post-release
instructions to the people who interact with the animal should be
the least onerous that are practicable.
While the protocols for handling radioiodine treatment of feline thyroid
conditions are well-established and
are incorporated explicitly into some
states’ regulations, there is no guidance for the care of dogs that have
received radionuclides for the treatment of skeletal conditions.
This study investigated the radiation safety restrictions for three
treatments that use radionuclides
on canine skeletal conditions. The
June 2020
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bone-seeking radiopharmaceutical,
153
Sm-1,4,7,10-tetraazacylcododeca
netetramethylenephosphonic acid
(153Sm-DOTMP), and a form of
brachytherapy that employs unencapsulated 90Y in a permanent,
interstitial implant are used to treat
osteosarcoma. Colloidal particles
labeled with 117mSn are used to
treat osteoarthritis.

MATERIALS AND
METHODS
Radionuclides
All three of these radionuclides
emit electrons, either as conversion electrons or as beta particles,
through which they deliver their
therapeutic effects. Two of the
three, 153Sm and 117mSn, also emit
photon radiation that could result
in external exposure. Their most
relevant characteristics are summarized in Table 1.
Treatments
Samarium-153-DOTMP is administered intravenously at dosages
in the range of 37–74 MBq kg−1.
About 40% of the administered activity is taken up by the skeleton,
and the remainder is excreted within
2 hours through the urinary system
(Simon et al. 2012). There is thus
the potential for radioactive contamination of a pet’s household and
thence internalization of 153Sm
by household members.
The 90Y implants are formulated as an unencapsulated particulate suspension that is designed to
remain at the site of implantation
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within a tissue. This material has
been injected under very low pressure (Stearns et al. 2015) into holes
that had been drilled into a bone
tumor. Activities totaling between
0.0% and 0.3% of the administered
amounts were observed in the excreta of eight rats that had received
intramuscular implants and were
observed for 6 or 10 days after implantation, while detectable activity
was found in the urine of some of
the treated dogs for up to 2 days.8
The maximum activity that has been
administered to a dog is 1.59 GBq.
The 117mSn radiosynoviorthesis
formulation is also a particulate.
This material has been used to treat
osteoarthritic canine elbows. Although some dogs were treated
with as much as 130 MBq per elbow
during clinical trials, the current
protocol is for the administered
activity to be determined by a
weight-based estimation of the
body surface area under the constraint of a maximum dosage of
111 MBq per elbow. In a study of
normal dogs, at six weeks after administration, less than 1% of the
administered activity had left the
joint space into which the material had been injected. About
0.7% of the administered activity
was found in the liver, 0.1% in
the spleen, and 0.1% in the excreta (Lattimer et al. 2016).
Dose limits
In the United States, human
patients to whom radionuclides
have been administered may be released from the licensee’s control if

Table 1. Relevant characteristics of the radionuclides analyzed in this investigation. The row labeled “G” is the published exposure rate constant for 153Sm and
117m

Sn and the estimated exposure rate constant from bremsstrahlung radiation

in bone for 90Y.
153

Sma

Physical Half-life
Electrons (mean energy keV)
Photons (keV)
“G” (nC kg−1 MBq−1 h−1 @ 1 m)

46.3 h
200–265
103 + others
0.336

90 b

Y

64.1 h
935
minimal
0.0105

117m

Snc

14.0 d
135
159
1.18

the maximum likely effective dose
equivalent to an individual who is
exposed to the patient is less than
5 mSv (US NRC 2007a, 2008). This
is higher than the annual limit of
1 mSv for the protection of the
general public. The National Council on Radiation Protection and
Measurements (NCRP) implies that
the infrequent exposure limit of
5 mSv for the general public could
be applied to veterinary treatments
(NCRP 2004), but it does not explicitly recommend it.
In each of the three canine radionuclide treatments that are analyzed in this report, there is a
concentration of the radioactivity
within a small volume of the overall
skeletal system. There is essentially
complete localization in the treated
region for the 90Y and 117mSn treatments, and it is unlikely that the tissues surrounding the treated area
would offer more than minimal
shielding, especially in the extremities. Thus, the contact dose was also
considered. Although there is no
regulation in the United States of
the doses to the skin or to the lens
of the eye of members of the public,
there are annual occupational
limits on these doses. The International Atomic Energy Agency (IAEA)
recommends dose limits to the skin
and to the lens of the eye of a member of the public that are equal in
value to one-tenth of the annual
limits in the United States for occupational exposure (IAEA 2009). These
figures are consistent with those in Table 6 of ICRP Report 103 (ICRP 2007).
Because an elevated limit for the
effective dose equivalent is not explicitly recognized for veterinary patients and there are no regulatory
limits on localized exposure to members of the general public, the recommendations in this report are based
upon the following limits, which
were derived from the regulatory
limits in the United States (US
NRC 2007b) as well as the recommendations of the IAEA and the

a

ICRP 2008; Smith and Stabin 2012.
Zanzonico et al. 1999; ICRP 2008.
c
Srivastava 2007; ICRP 2008; Smith and Stabin 2012.
b
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International Commission on Radiological Protection.
• Annual effective dose equivalent to the most exposed person:
1 mSv; and
• Annual localized dose to the
surface of an exposed person:
50 mSv at a depth of 70 microns
averaged over 10 cm2 as the
skin dose and 15 mSv at a depth
of 3 mm averaged over 1 cm2 as
the dose to the lens of the eye.
Simulations
The dose in tissue at a distance
of 1 m through air from a point
source of 117mSn and the doses in
tissue at various depths from a superficially located source of 153Sm,
90
Y, or 117mSn that resembles a bone
tumor or a treated joint were simulated using Monte Carlo software (GATE version 6.2, 7.2, or
8.0, Open GATE Collaboration)
(Jan et al. 2004). The radionuclide
sources were defined using the ICRP
107 decay scheme data (ICRP 2008).
None of the tabulated emissions
was excluded, regardless of energy
or abundance.
For the 153Sm and 90Y treatment simulations, the “bone” was
30 cm in length, of which the middle 5-cm segment was a “lesion.”
The bone had a central core with
a diameter of 1.6 cm and material
properties resembling trabecular
bone (using the GATE material
“SpineBone”) surrounded by a
2-mm-thick layer with material
properties resembling cortical bone
(using the GATE material “RibBone”).
It had an overall diameter of 2 cm
and was covered by 2.5 mm of tissue.
This is shown in top and side views in
Fig. 1 and Fig. 2. The tissue that was in
contact with the bone is also shown.
Although 153Sm-DOTMP is
presumed to be taken up by and
distributed on the surfaces of the
trabecular and cortical bone, data
on the bone surface area of the
dog have not been found in the
literature, so both 153Sm and 90Y
were treated as being distributed
uniformly within the entire volume
704

FIG. 1. A top-down view of a cross-section through a central plane of the simulation of the
treatments with 153Sm and 90Y. The rectangle at the top of the figure is the block of tissue, which
is pressed up against the treated limb. It is 5 cm thick, 10 cm wide (in the direction of the limb)
and 30 cm high (perpendicular to the direction of the limb). The inner core of the simulated
bone has a radius of 8 mm and the material properties of trabecular bone while the 2-mm-thick
outer sheath has the material properties of cortical bone. A 2.5-mm-thick sheath with the properties of tissue surrounds the bone. For 153Sm and 90Y, the radionuclide was uniformly distributed within both the trabecular and cortical portions of the central segment of the bone in
order to simulate a lesion. For 153Sm the portions of the bone that are adjacent to the portion
simulating the lesion had one-tenth of the activity of the central portion; whereas for 90Y the
bone outside of the lesion contained no radioactivity.

of the lesion for the purpose of determining the activity in the lesion.
The skeletal mass was assumed to
be 14% of the total body mass of
the dog. This value is higher than
the 10% estimate from the University of Florida 26-kg dog model
(Padilla et al. 2008) and lower than
the 20.6% estimate in a literature
survey (Lindstedt and Schaeffer
2002), but it is consistent with the
13–14.5% skeletal mass of adult human models (ICRP 2002) with total
body masses of 60–73 kg. The lesion
with a volume of 15.7 cm3 would
thus constitute 0.308% of the skeletal
mass of a 70 kg dog, assuming a bone
density of 1.92 g cm−3 (ICRU 1989).
In the case of 153Sm, radioactivity was distributed along a 15-cm
length of the bone with a 10:1 ratio
of activity in the 5-cm-long lesion
to that in the 5-cm-long adjacent
segments of the normal bone. This
is shown in top and oblique views
in Fig. 1 and Fig. 2.
For simulation purposes, the
activity in the lesion may be estimated by taking the administered
activity times the skeletal uptake
fraction times the fraction of the
skeletal mass accounted for by the
lesion times the lesion-to-normal
ratio of the uptake in the lesion. An
administered activity of 74 MBq kg−1
of 153Sm-DOTMP to a 70-kg dog,
which is slightly more than the
highest actually administered dosage
www.health-physics.com

of 67.3 MBq kg−1 in the canine studies, would lead to 63.8 MBq in the
“lesion.” The two adjacent 5-cm
lengths of normal bone in the simulation would contain 6.38 MBq,
assuming the simplified case of instantaneous uptake by the skeleton and instantaneous clearance
from the soft tissues.
In the simulation of 90Y brachytherapy, which is a highly localized treatment by virtue of its
administration as an implant, the
radioactivity was uniformly distributed within the lesion and nowhere else in the simulated bone.
For the 117mSn radiosynoviorthesis simulation, a stylized ball
and socket joint as shown in Fig. 3
and Fig. 4 was modeled. The activity was concentrated on the surfaces of the synovial membrane,
which was modeled as a cylindrical
surface surrounding the rest of the
joint. Concentrating the activity
in the synovium is consistent with
measurements showing that there
is negligible remaining activity in
the synovial fluid within a few days
after administration.9
The dose to tissue that is in
contact with the treatment site
was assessed in a block of material
that had the properties of soft tissue
and was 5 cm thick, 30 cm long,
and 10 cm wide. It was positioned
9

Unpublished data.
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FIG. 2. An oblique view of the simulations of 153Sm and 90Y. The block of tissue is rendered as a
wireframe of a rectangular prism that is 5 cm thick, 10 cm wide and 30 cm high. The segment of
the bone simulating the lesion is the brighter area in the center of the cylinder that is in contact
with the tissue block.

touching a simulated limb with its
long axis parallel to the 10-cm dimension so that the source was centered on the 30 cm  10 cm face.
Two billion events were simulated for each situation. The number of events divided by the sum
of the yields or abundances of all
of the emissions of the source gives
the number of disintegrations, or
Bq s, that were simulated. Doses
in the tissue block were averaged
over an area of 10 cm2 at a depth
of 70 um from the surface of the
block that was touching the limb
and over an area of 1 cm2 at a
depth of 3 mm from that surface
of the block. Both analysis areas
were centered on the peak of the
dose distribution.
Operational Radiation Safety

Exposure rate measurements
The external exposure rates from
the 153Sm and 117mSn treatments
were measured using calibrated

ionization survey meters (Model
9DP, Ludlum Measurements, Inc.,
Sweetwater, TX). These treatments
were performed at different sites,
and a different meter was used at
by each site. A correction factor
was determined for each of these
radionuclides.
For 117mSn radiosynoviorthesis,
which is typically administered into
an appendicular joint with only the
thin surrounding tissue to attenuate
its photon emissions, the numerator
of the correction factor was obtained
by calculating the dose rate constant
in air for each photon emission separately using the method described
by Smith and Stabin (2012) and
then summing them. The denominator was obtained by calculating
the weighted sum of the dose rate
constants of the individual photon
emissions using the energy responses of the meter at each energy (Ludlum Measurements, Inc.
2017) as the weights. The correction
factor for 117mSn was calculated to
be 1.45.
In the case of 153Sm-DOTMP,
which is distributed throughout
the entire skeleton, the spectrum of
the emissions is modified by the attenuation of the whole body, which
is akin to the beam-hardening
phenomenon in x-ray imaging
(Bushberg et al. 2012). Treating
the skeleton as the source organ,
the transmission factor for each photon energy was estimated from the
absorbed fractions at each photon
energy in the whole body in the

FIG. 3. A top-down view of a cross-section through the central plane of the simulation of
117m
Sn. The tissue block is the same as in the other simulations. The joint is a stylized ball
and socket joint. Layers of cartilage lie between the ball to the left and the socket to the right
in the figure. The synovium in which the radioactivity was uniformly distributed is transparent
in this figure. It is a thin cylindrical layer that surrounds the joint between the solid cylinders of
bone. The bone and joint are 1.5 cm in radius. The superficial tissue is 2 mm thick.
www.health-physics.com
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FIG. 4. An oblique view of the simulation of 117mSn. The synovium is rendered as the lighter
band in the center of the limb.

University of Florida canine model
(Padilla et al. 2008). The numerator of the correction factor was
the sum of the dose rate constants
for each emission times the corresponding transmission factor for
each emission. The denominator of
the correction factor was a weighted
sum of those dose rate constants
where the weighting factors were
the products of the transmission
factor and the energy response of
the ionization meter for each photon emission. The correction factor
was calculated to be 1.24 when the
shielding effect of the whole body
from the University of Florida canine model was included compared
to a factor of 1.35 for a source of
153
Sm in air.
Animal studies
Samarium-153-DOTMP. Nine
dogs were administered 37–74
MBq kg −1 of 153 Sm-DOTMP to
treat spontaneous osteosarcoma.
They weighed 37–62 kg and ranged
in age from 3–9 y.
The external exposure rate was
measured at a distance of 1 m by
one of the ionization survey meters.
The raw readings were corrected for
the energy response of the meter
by the factor of 1.24. Measurements
were performed at times of 3, 24, 48,
72, and 96 h after administration.
The exposure rates were normalized
706

by the activity that had been administered and then were fit by a single
exponential decay curve that was
constrained to reach a final value
of zero (Prism, GraphPad Software,
La Jolla, CA).
In an earlier study, four dogs
that had osteosarcomas and that
weighed 32–55 kg had been administered 37 MBq kg−1 and imaged
21–24 h later using a planar gamma
camera with a low-energy, parallelhole collimator (Selting et al. 2011).
Those image data were re-analyzed
for the present study. Regions of interest were drawn around the bone
lesions and over an area of the adjacent bone with a normal appearance and the counts per pixel in
each were determined for the purpose of estimating the lesion-tonormal uptake ratio.

Yttrium-90 interstitial
implants. No external exposure
rate measurements that had been
made shortly after treatment were
recorded. Anecdotally and qualitatively, activity has been detectable
in the dogs’ urine for up to 2 days after treatment with some of the early
formulations of the material.10
Tin-117m radiosynoviorthesis. Twelve adult dogs that were
suffering from Grade 3 osteoarthritis
10

Unpublished data.
www.health-physics.com

of the elbow were studied. Nine received treatments of both elbows
and three were treated in only one
elbow. The nominal dosage to a single elbow of a 22.7 kg dog was 64.8
MBq. The nominal administered activity was scaled by a weight-based
estimate of the dogs’ body surface
area according to a chart of fixed
dosages for weight ranges in increments of 4.5 kg. The dogs’ weights
ranged from 22.7 to 45.9 kg. The total activity that was administered to
each dog averaged 137 MBq with a
range from 59.2 to 207 MBq.
The external exposure rate was
measured using the other of the
two ionization survey meters and
was corrected for the energy response of the meter by the factor
of 1.45. The exposure rate was
measured at a distance of 1 m from
the center of the chamber to the
nearest surface of the dog’s closer
elbow from each side and from in
front of the dog. These measurements were made as soon as the
dog had recovered from the sedation of the procedure and then
again the next day, nominally
24 h later.
In order to calculate the expected external exposure rate, the
distance between the proximal
and distal elbows is needed, but
that distance had not been measured. In a separate cohort of 24
dogs of various breeds and both
sexes ranging in weight from 2.5
to 44.9 kg, the distance between
their elbows was measured while
they were standing. On the assumption that the distance would
scale roughly with the cube root of
their masses, a linear fit of the
cube root of their masses to their
elbow-to-elbow distances subject to
the constraint that it pass through
the origin was performed and found
to be
pﬃﬃﬃﬃﬃ
Delbows ¼ 5:68 3 W;

ð1Þ

where Delbows is the elbow-to-elbow
distance in centimeters and W is
the mass of the dog in kilograms.
The resulting distance was used to
June 2020
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adjust the expected exposure rate
for the effect of the inverse square
law on the contribution to the exposure by the distal elbow.
A qualitative assessment of the
excreted activity was made by
collecting 20–50 cc of the dogs’
urine at each time point. The exposure rates that were measured when
the meter was placed right next to
the urine containers were indistinguishable from background.
Exposure models
The standard model in NUREG
1556, Volume 9, Appendix U, Revision 2 (US NRC 2008), hereinafter
referred to as “NUREG-1556” or
“the regulatory guidance,” for estimating the dose to the most exposed person is to assume that
that person spends a fraction of
each day at a distance of 1 m from
the patient that has received the radionuclide therapy. That fraction is
typically 0.25 (i.e., 6 h a day) when
the physical half-life (or the effective half-life, if it is known) of the
radionuclide exceeds a day.
It is not uncommon that pets
sleep with their owners. For normal interaction with a pet or a
working dog during waking hours,
a person could be instructed to
avoid more than brief contact with
the treated anatomical area of the
dog, and thus prolonged contact
between a particular spot on the
body of that person and the highest
activity area of the dog while they
are awake is unlikely. However,
when sleeping, it is conceivable
that the point on the surface of
the dog with the highest dose rate
could touch a particular spot on
the person for some time. The average number of times that a person shifts position while sleeping
is reported to vary from 2.1 times
an hour among the elderly to 4.7
times an hour for pre-teenagers
(De Koninck et al. 1992). The literature documents that dogs also do
not typically remain perfectly still
for long times while asleep (Hansen
et al. 2007; Dow et al. 2009; Patel
et al. 2017).
Operational Radiation Safety
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Internalized dose
If the dog’s environment were
to become contaminated by the
administered activity, it could be
possible for people to ingest some
of the radionuclide and thereby to
receive an internal dose. The approach in the regulatory guidance
of assuming that a fraction of the
administered activity would be internalized by a person (Eckerman
et al. 1988; US NRC 2008) and applying a dose conversion factor to
that internalized activity is used
here to estimate how significant
the internalized dose might be.

RESULTS
External exposure
Samarium-153-DOTMP.
The measured external exposure
rate data from the dogs that were
treated with 153Sm-DOTMP are plotted in Fig. 5.
The effective half-life of the external exposure rate measurements
was 44.6 (95% CI: 33.8–65.8) h,
which is close to the physical
half-life of 153Sm of 46.3 h. The
next-day imaging studies showed
essentially only skeletal uptake. This
is consistent with the rapid urinary
clearance of 153Sm-DOTMP that
has been measured in rats (Simon
et al. 2012) in which an effective
half-life of 0.5 h was estimated for

the urinary activity. Since the first
canine measurement was taken 3 h
after administration and the external exposure rate readings are fit
well by a single exponential decay
function, these measurements are
those of the radioactivity that was
taken up by the skeleton. The exposure rate per unit administered activity extrapolated back to the time of
administration was 0.122 (95% CI:
0.101–0.142) nC kg−1 MBq−1 h−1
at 1 m.
The average ratio of the counts
in the lesion and in adjacent bone
in the four dogs that underwent
gamma camera imaging was 12.7:1
(95%CI: 7.17:1–18.3:1). Similar radiopharmaceuticals have been reported to have tumor-to-normal
background ratios of 4.0 to 11.0
in a rat model of bone tumors
using mechanical trauma (Ghiron
et al. 1991). One dog had more
than twice the ratio of the average
of the other three. Excluding the
data from that dog, the average ratio
was 9.5:1 (95%CI: 8.55:1–10.4:1).
This is the basis of the 10:1 lesionto-adjacent ratio that was used in
the simulation of a typical lesion.
Adapting the model that is
found in NUREG-1556 in which
the patient spends a fraction of a
day at a distance of 1 m from the
most exposed person, the dose to
the most exposed person would be

FIG. 5. Fit of a single exponential decay curve to the exposure rate measurements of 153SmDOTMP in dogs. The fit was constrained to reach zero. The dashed lines show the 95% confidence interval of the fit. This curve is dominated by the uptake in the skeleton. The fit to the
curve is 0.122e−ln 2t/44.6 nC kg−1 MBq−1 h−1. The R2 value of the fit is 0.562.
www.health-physics.com
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D¼

Teff
meas E ¼ 7:14  10−5 mGy MBq−1 ; ð2Þ
In2

where the effective half-life, Teff, is
44.6 h, the measured exposure
rate, Xmeas, is 0.122 nC kg−1 MBq−1
h−1 at 1 m, the occupancy factor,
E, is 0.25 or 6 h a day, since the effective half-life exceeds 1 d, and
the f-factor of 153Sm is 36.4 Gy C−1
kg (Smith and Stabin 2012). An
administered activity of 14.0 GBq
would be needed to impart 1 mSv
to the most exposed person under
these conditions.

Yttrium-90 interstitial
implant. The external exposure
from 90Y interstitial implants was
assumed to arise only from bremsstrahlung x rays that are generated
in bone, which have been estimated to have an exposure rate constant of 10.5 pC kg−1 MBq−1 h−1 at 1
m (Zanzonico et al. 1999). The maximum administered activity to date
of 1.59 GBq would deliver a negligible whole body dose of 14.0 mSv
using the NUREG-1556 approach.
Tin-117m radiosynoviorthesis. No significant difference
was observed in the initial and
next day readings from the dogs
that were treated with 117m Sn radiosynoviorthesis, which implies
that most of the administered activity was retained in the joint
and little, if any, of it either had
leaked out of the injection tract or
had already been transported into
the lymphatic system. This agrees
with another study that showed
99.1% retention in the joint at 42
d (Lattimer et al. 2016).
The dose rate constant from
the simulation of a point source
in air was 1.221017 Gy m2 Bq1
s1. This falls between the published
values of 1.201017 Gy m2 Bq1
s1 (Smith and Stabin 2012) and
1.891017 Gy m2 Bq1 s1 (Shleien
et al. 1998). The external exposure
rate readings were compared to the
exposure rates that were expected,
given the dose rate constant from
the simulation at 1 m, the activity
that was administered to each elbow,
and the distance-correction of the
708
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contribution of the farther elbow.
The linear fits of these data, which
were constrained to pass through
the origin, were
• Left Lateral: Xmeas = 0.703 Xexp;
• Right Lateral: Xmeas = 0.704
Xexp; and
• Cranial: Xmeas = 0.680 Xexp.
where Xmeas is the measured exposure rate at 1 m and Xexp is the expected exposure rate of a bare
source in air. Thus, for protection
purposes, the dose rate constant
of 8.5410−18 Gy m−2 Bq−1 s−1 at
1 m is used. This is derived from
the lateral measurements, which
are 70% of the dose rate constant
of a bare source in air.
The total dose at a distance of
1 m from a dog that has received
the maximum treatment to both
elbows, which would total 222
MBq, can be estimated using eqn
(2) above, assuming an occupancy
factor of 0.25 and an effective
half-life of 14 d, and replacing the
exposure rate, Xmeas, by the product of the dose rate constant and
the administered activity. In this
scenario, it is 0.827 mSv. The maximum measured exposure rate, 152
nC kg−1 h−1 at 1 m from a dog that
had received 206 MBq, gives a total
dose of 0.671 mSv using eqn (2)
with these assumptions.
Contact doses
The contact doses that are
based upon the simulations of the
three radionuclides are given in
Table 2.
One can calculate the total
dose to a patch of skin or to the lens
based upon these contact doses, Dc,
the activity in the lesion or joint,
AL, the occupancy factor (i.e., the

fractional duration) of the contact,
E, and the delay between treatment
and the first such contact, D, according to the expression
D¼

Teff
− In2D
DC AL Ee Teff ;
In2

ð3Þ

where Teff is the effective half-life.
There are many combinations of
the values of these parameters that
can satisfy the dose limits of
50 mSv to the skin and of 15 mSv
to the lens of the eye. Table 3
shows just one such set of values
for each treatment.
Internalized dose
The maximum administered
activities, dose conversion factors,
and estimated internalized doses
based upon a 10 ppm internalization are shown in Table 4.

DISCUSSION
The dose limits that were employed in this study are quite conservative. The annual total effective
dose equivalent of 1 mSv is that
which is allowed in the United
States for a member of the general
public, even though a pet dog’s family members could be presumed to
derive a compensatory benefit from
a higher exposure to the treated pet
in a similar argument to the rationale for allowing a 5 mSv dose limit
to the person receiving the most exposure from a human patient. None
of these three treatments typically
requires that the treated dog be
quarantined for safety reasons based
upon the total dose to a person who
spends 6 hours a day at a distance of
1 m from the dog. Such exposure to
the dog may commence immediately after treatment without exceeding the limit.

Table 2. The contact doses for skin and the lens of the eye from each of the three
treatments based upon Monte Carlo simulations.
Treatment

Skin dose
(10 cm2 @ 70 mm)

Lens dose
(1 cm2 @ 3 mm)

Sm-DOTMP (Gy Bq−1 s−1)
Y Interstitial Implant (Gy Bq−1 s−1)
117m
Sn Radiosynoviorthesis (Gy Bq−1 s−1)

7.2410−15
2.6110−13
2.7610−14

7.6410−15
2.0110−14
2.8010−14

153
90
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In considering contact doses,
the assumption that the same precise patch of skin of a person would
be in direct contact with the point
on the dog that has the highest
dose rate for an hour a day is conservative, given that both the person and the dog are likely to move
about. The assumption that a person’s eye, even closed, would be
touching the highest dose rate
point on the dog for any length of
time that even approaches an hour
a day is unrealistic, given the discomfort to the person in such a scenario. It should be noted that if a
dog’s coat has not been clipped for
the treatment, even compressed
fur would offer an additional separation of the person and the treated
area and thus lead to a lower skin or
lens dose than that from direct contact with the dog’s skin.
The estimated maximum internalized doses to people that are
shown in Table 4, which are based
upon the 10 ppm assumption in
NUREG-1556 for human patients,
are negligible for all three treatments.
To reduce the potential internalized
dose from excreted radioactivity further, one could isolate a treated dog
until it has voided most of the administered activity that is likely to
be excreted. To this end, it would be
prudent to quarantine dogs that
have been treated with 153SmDOTMP for 4 h, which was eight
effective half-lives of the activity
in the urine in a preclinical murine
study (Simon et al. 2012). Based

Table 4. The internalized dose estimates for each of the three treatments assuming the given maximum administered activities and 10 ppm internalization.
153
SmDOTMP

Maximum Administered
5.18
Activity (GBq)
10 ppm Internalized
51.8
Activity (kBq)
Dose Conversion Factora (Sv Bq−1) 8.0710−10
Internalized Dose (mSv)
41.8

90

Y Interstitial
implant

117m
Sn
Radiosynoviorthesis

1.59

0.222

15.9

2.22

2.9110−9
46.3

7.9710−10
1.77

a

Eckerman et al. 1988.

upon the authors’ clinical observation of slight 90Y excretion for up
to 2 days11 one might quarantine
dogs that have been treated with
90
Y interstitial implants for 2 days.
Future improvements in liquid
brachytherapy technology could
reduce the duration of this quarantine. It should be ensured that
the treated dogs have actually
voided before their release, as, on
rare occasions, dogs have been
known to retain their urine for as
long as 4 days when boarded in a
strange kennel.11 No quarantine
for excretory reasons is warranted
for 117mSn radiosynoviorthesis.
The dog’s owner should be
given instructions for how the dog
should be allowed to interact with
people and with the home or work
environment in order to make it unlikely that the dose limits would be
exceeded. If there is the potential
for retreatment during the period
covered by the annual dose limit,
11

Unpublished data.

the instructions for each treatment
should be designed to reflect the total annual dose.

CONCLUSION
It is compliant with the US regulatory limit on the annual dose to a
member of the general public to release to their owners immediately after treatment dogs that have received
any of these radionuclide treatments
in commonly administered activities. People should avoid prolonged
touching of the treated region and
should not sleep with the treated
dog for three weeks following an interstitial implant of 90Yor for a month
following 117mSn radiosynoviorthesis.
No such avoidance of direct contact is necessary for 153Sm-DOTMP.
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